Peptide-Targeted Liposomes for Cancer

Peptide-Targeted Liposomes

5-8x uptake increase

Dual-ligand peptide-functionalized liposomes achieved 5-8 fold higher tumor cell uptake than unfunctionalized carriers in glioma models.

Chen et al., ACS Applied Materials & Interfaces, 2017

Chen et al., ACS Applied Materials & Interfaces, 2017

View as image

Liposomes are spherical vesicles made from phospholipid bilayers, the same material that forms cell membranes. Pharmaceutical liposomes have been used since the 1990s to deliver chemotherapy drugs, with Doxil (liposomal doxorubicin) becoming the first FDA-approved nanomedicine in 1995. These early liposomes relied on passive targeting: they accumulated in tumors through the enhanced permeability and retention (EPR) effect, where leaky tumor blood vessels allow nanoparticles to seep into tumor tissue while normal vessels keep them out. The problem is that passive targeting is inefficient. Only 0.7% of administered nanoparticles typically reach the tumor. Peptide functionalization changes this equation. By attaching tumor-targeting peptides to the liposome surface, researchers convert passive carriers into active seekers that recognize and bind specific receptors overexpressed on cancer cells.^[1] This article covers the full landscape of peptide-targeted liposomal drug delivery, from mechanism to clinical relevance. For related nanotechnology approaches, see our articles on peptide-coated nanoparticles for cancer and self-assembling peptide nanostructures.

How Peptide-Targeted Liposomes Work

A standard pharmaceutical liposome is a sphere roughly 80-200 nm in diameter, composed of a phospholipid bilayer enclosing an aqueous core. Hydrophilic drugs dissolve in the core; hydrophobic drugs embed in the lipid membrane. PEGylation (coating with polyethylene glycol chains) extends circulation time by preventing immune system recognition, creating so-called "stealth" liposomes.

Peptide targeting adds a third layer of engineering. Short peptide sequences (typically 5-30 amino acids) are conjugated to the distal ends of PEG chains on the liposome surface, where they extend outward like antennae. When these peptides encounter their target receptor on a cancer cell, they bind and trigger receptor-mediated endocytosis, pulling the entire liposome and its drug cargo into the cell. This active targeting mechanism works through two primary strategies: receptor-binding peptides that recognize tumor-overexpressed surface markers, and cell-penetrating peptides (CPPs) that physically breach cell membranes regardless of receptor expression.^[2]

The distinction matters. Receptor-binding peptides (RGD, angiopep-2, GE11) provide tumor selectivity: they preferentially deliver drugs to cells that overexpress the target receptor. Cell-penetrating peptides (TAT, poly-arginine, CPP44) provide enhanced uptake: they drive more drug into cells but lack inherent selectivity. The most advanced systems combine both, using a receptor-binding peptide for tumor selectivity and a CPP for enhanced internalization.

RGD Peptides: Targeting Tumor Blood Vessels

The tripeptide motif arginine-glycine-aspartate (RGD) binds integrin receptors alphavbeta3 and alphavbeta5, which are overexpressed on the endothelial cells of tumor blood vessels and on many tumor cell types. Integrins are transmembrane glycoproteins that mediate cell adhesion to the extracellular matrix and regulate signaling pathways involved in cell survival, migration, and proliferation. In tumors, integrin overexpression marks actively growing vasculature and migrating cancer cells, making integrins an attractive targeting handle. RGD-functionalized liposomes represent the most extensively studied peptide-targeted liposomal system, with research spanning breast, prostate, lung, brain, and pancreatic cancers.

Mahmoudi and colleagues demonstrated that RGD-decorated liposomes loaded with curcumin (RGD-Lip-Cur) showed dose-dependent cytotoxicity against MCF-7 breast cancer cells. Flow cytometry and caspase assays confirmed enhanced cellular uptake and apoptosis induction compared to non-targeted liposomes or free curcumin. The liposomes had a mean diameter of approximately 100 nm and maintained structural stability during storage.^[3]

The cyclic form of RGD (cRGDfK) binds integrins with higher affinity and selectivity than linear RGD because the cyclic constraint locks the peptide into its bioactive conformation, reducing entropic penalties upon receptor binding. This structural advantage translates to roughly 10-fold higher binding affinity in many assay systems. Multivalent display (presenting multiple RGD copies per liposome) further enhances avidity by engaging several integrin receptors simultaneously on the same cell surface.

RGD peptide liposome strategies face challenges including non-specific binding to serum proteins, immune system recognition, and heterogeneous integrin expression across tumor types. The integrins targeted by RGD are expressed on normal endothelial cells during wound healing and inflammation, creating off-target binding potential. Despite two decades of development, no RGD-liposome formulation has reached late-stage clinical trials, reflecting the broader difficulty of translating nanoparticle targeting from mouse models to human patients.

Crossing the Blood-Brain Barrier

Brain tumors present a unique challenge: drugs must cross the blood-brain barrier (BBB) before reaching the tumor. Peptide-functionalized liposomes offer a solution by incorporating BBB-crossing peptides alongside tumor-targeting peptides.

Chen and colleagues engineered liposomes dual-functionalized with Peptide-22 (which binds the low-density lipoprotein receptor on BBB endothelial cells) and cyclic RGD (which targets integrins on glioma cells and tumor vasculature). In C6 glioma-bearing mice, these dual-targeted liposomes achieved significantly higher brain tumor accumulation than either single-peptide system. The Peptide-22 component mediated transcytosis across the BBB, while the cRGD component directed accumulation specifically within the tumor mass. Doxorubicin-loaded dual-peptide liposomes produced the strongest antiglioma efficacy among all tested formulations.^[4]

The dual-targeting approach addresses a problem that has stalled brain tumor nanomedicine for decades. Liposomes that cross the BBB efficiently tend to distribute throughout normal brain tissue, causing neurotoxicity. Liposomes that target tumor cells cannot reach them because the BBB blocks entry. By separating the two functions onto two different peptides on the same carrier, the Chen system crosses the barrier first and targets the tumor second, creating a sequential targeting cascade.

Jourdain and Eyer reviewed the broader landscape in 2024, noting that peptide-based strategies for glioblastoma have gained traction because peptides combine BBB-targeting properties with the ability to drive cargo deep into tumor tissue. Angiopep-2 (which binds LRP1), T7 (which binds transferrin receptor), and D-SP5 are among the most studied BBB-crossing peptides for liposomal brain delivery. The choice of BBB-crossing peptide depends on which receptor is most expressed on the patient's BBB endothelium, as receptor expression varies between individuals and between tumor-adjacent and normal brain vasculature.^[5]

Muolokwu and colleagues extended this concept to Alzheimer's disease in 2025, creating transferrin-receptor-targeting and CPP-functionalized liposomal nanocarriers for brain delivery of therapeutic antibodies. The nanocarriers successfully delivered anti-amyloid antibodies across the BBB in vitro models. This demonstrates that the peptide-liposome BBB-crossing platform is generalizable beyond oncology to any condition where brain delivery is the bottleneck.^[6]

Dual-Ligand and Multi-Functional Systems

The most promising peptide-targeted liposomes use multiple ligands simultaneously. This dual-ligand approach addresses a fundamental limitation: single targeting peptides rarely provide both selectivity and penetration.

Lin and colleagues designed liposomes bearing both an anti-GPC3 antibody (targeting glypican-3, which is specifically expressed on hepatocellular carcinoma cells) and CPP44 (a cell-penetrating peptide that enhances internalization). The dual-ligand system significantly increased arsenic trioxide delivery to HCC cells compared to either single ligand, demonstrating that receptor-mediated selectivity and CPP-driven uptake are additive rather than redundant.^[7]

Salahi and colleagues investigated how the conjugation method of targeting agents affects performance. They compared different arrangements of poly-L-arginine (a CPP) and chondroitin sulfate (a CD44-targeting ligand) on nanoliposomes delivering mitomycin C to triple-negative breast cancer cells. The manner of peptide conjugation, not just the choice of peptide, significantly affected cellular uptake and cytotoxicity. Tandem conjugation (both ligands on the same PEG chain) outperformed parallel conjugation (separate PEG chains) for certain configurations.^[8]

Tumor-Homing Peptides for Specific Cancers

Beyond broad-spectrum targeting with RGD, researchers have identified peptides that home to specific tumor types. These peptides bind receptors uniquely overexpressed on particular cancers, potentially reducing off-target effects.

Zhang and colleagues developed CKAAKN peptide-conjugated long-circulating nanoliposomes for pancreatic cancer. CKAAKN is a homing peptide identified through phage display that selectively binds pancreatic cancer cells. The CKAAKN-nanoliposomes (approximately 100 nm, loaded with oridonin from Rabdosia rubescens) selectively internalized into BxPC-3 pancreatic cancer cells within 1-4 hours in vitro and showed tumor-targeting accumulation in xenograft mouse models. The PEGylated formulation maintained good stability and biosafety.^[9]

Yu and colleagues applied the same principle outside oncology in 2026, using a cardiac homing peptide to functionalize nanoliposomes for targeted atorvastatin delivery to ischemic myocardium in a myocardial infarction model. The peptide-functionalized nanoliposomes (Ato@DSPE-PEG-CHP) achieved precise delivery to infarcted cardiac tissue, demonstrating that the peptide-targeted liposome platform extends to any tissue with an identifiable peptide-receptor pair.^[10]

Immune-Priming Peptide Liposomes

A distinct application uses peptide-functionalized liposomes not as drug carriers but as vaccine platforms that prime the immune system to attack tumors. Zahedipour and colleagues tested a VEGFR2-targeted nanoliposomal peptide vaccine combined with paclitaxel chemotherapy in melanoma mouse models. Prior work had shown the nanoliposomal peptide vaccine alone enhanced immune and antitumor responses; the combination with paclitaxel produced further synergy by simultaneously killing tumor cells (chemotherapy) and training the immune system to recognize tumor vasculature (peptide vaccine). The combination modulated the tumor microenvironment and boosted immune activation beyond either therapy alone.^[11]

This immune-priming approach represents a conceptual shift: the liposome delivers not a cytotoxic drug but a peptide antigen that triggers an anti-tumor immune response. The liposomal formulation protects the peptide from degradation and provides adjuvant effects through its lipid components. Cationic liposomes in particular can activate dendritic cells and enhance antigen presentation, making them natural vaccine carriers.

The peptide vaccine liposome concept is especially relevant for tumors with known peptide neoantigens. By loading patient-specific tumor peptide antigens into liposomal carriers, personalized cancer vaccines can present these antigens to the immune system in an immunostimulatory context. Several clinical trials are exploring this approach for melanoma, non-small cell lung cancer, and pancreatic adenocarcinoma.

Stimulus-Responsive Peptide Liposomes

Smart peptide-liposome systems incorporate environmental triggers that activate at the tumor site. Wang and colleagues designed pH-sensitive nanoliposomes modified with a CD47 mimicry peptide. CD47 is a "don't eat me" signal that prevents macrophage phagocytosis; the mimicry peptide extends circulation time by fooling the immune system. At the acidic pH of the tumor microenvironment (pH 6.5-6.8), the pH-sensitive lipid component destabilizes, releasing the drug payload specifically within tumor tissue.^[12]

This dual-functional design addresses two problems simultaneously: immune evasion during circulation (CD47 peptide) and selective drug release at the tumor (pH sensitivity). Similar strategies use matrix metalloproteinase (MMP)-cleavable peptide linkers that detach the PEG corona when cleaved by tumor-secreted MMPs, exposing cell-penetrating peptides underneath. MMP-2 and MMP-9 are particularly attractive triggers because they are overexpressed in the stromal tissue surrounding most solid tumors, creating a protease-rich environment that can selectively activate drug release.

The sequential activation concept, where the liposome remains inert during circulation and then "switches on" at the tumor site, addresses one of the oldest problems in targeted drug delivery. Early peptide-targeted liposomes suffered from premature drug release, peptide degradation by serum proteases, and immune clearance. Stimulus-responsive designs reduce these losses by keeping targeting peptides hidden or inactive until environmental cues confirm that the liposome has reached tumor tissue. The tradeoff is system complexity: each additional stimulus-responsive element adds manufacturing steps and potential failure modes.

The Pipeline at a Glance

Limitations and Open Questions

Clinical translation gap. Despite hundreds of preclinical studies, no peptide-targeted liposome has reached Phase III clinical trials for cancer. The gap between in vitro/in vivo efficacy and clinical reality remains the central challenge. Factors include manufacturing complexity, batch-to-batch variability in peptide conjugation density, and the unpredictable behavior of the EPR effect in human tumors (which is far more heterogeneous than in mouse xenografts).

Integrin expression heterogeneity. RGD-targeted liposomes assume uniform integrin overexpression across tumor tissue. In practice, integrin expression varies between tumor regions, between primary and metastatic sites, and between patients. A liposome optimized for one patient's integrin profile may underperform for another.

PEG dilemma. PEGylation is necessary for long circulation times, but the PEG corona can sterically shield targeting peptides from reaching cell-surface receptors. This "PEG dilemma" has driven the development of cleavable PEG linkers and stimulus-responsive systems, but adds manufacturing complexity. Some patients also develop anti-PEG antibodies after repeated dosing, accelerating clearance.

Endosomal escape. Even when peptide-targeted liposomes successfully enter tumor cells via endocytosis, many become trapped in endosomes and lysosomes, where the acidic environment degrades the drug cargo before it reaches its intracellular target. Cell-penetrating peptides partially address this through membrane disruption, and pH-sensitive lipid formulations can destabilize the endosomal membrane, but endosomal escape efficiency remains a bottleneck. Studies estimate that fewer than 2% of endocytosed nanoparticles escape into the cytoplasm in most systems.

Scale-up challenges. Laboratory preparation of peptide-functionalized liposomes involves multiple steps (lipid film formation, extrusion, peptide conjugation, purification, characterization) that are difficult to reproduce at pharmaceutical manufacturing scale. Consistent peptide density on the liposome surface is critical for targeting efficiency but hard to control at scale. A liposome with too few peptides will not bind its target; too many peptides can trigger immune recognition or cause aggregation. Current good manufacturing practice (cGMP) standards for conventional liposomes are well established, but adding peptide conjugation introduces additional quality control requirements that most manufacturing facilities are not yet equipped to handle.

Mouse-to-human translation. The EPR effect, which drives nanoparticle accumulation in tumors, is robust in mouse xenograft models but highly variable in human cancers. Many human tumors have poor EPR characteristics, meaning the baseline upon which peptide targeting builds may be weaker than animal studies suggest. Imaging studies in cancer patients receiving liposomal drugs show that EPR-mediated tumor accumulation varies by an order of magnitude between patients with the same cancer type.

Conjugation Chemistry: How Peptides Attach to Liposomes

The method used to attach peptides to liposome surfaces directly impacts targeting efficiency, stability, and reproducibility. Three primary conjugation strategies dominate:

Pre-insertion involves synthesizing peptide-PEG-lipid conjugates (such as peptide-PEG-DSPE) before liposome formation. The conjugate is mixed with other lipid components during the thin-film hydration step. This approach produces the most uniform peptide density but limits the types of peptides that can survive the liposome formation process.

Post-insertion attaches peptide-PEG-lipid micelles to preformed liposomes. The peptide-lipid conjugate spontaneously inserts its lipid anchor into the liposome bilayer when incubated at elevated temperature. This method allows sensitive peptides to avoid harsh preparation conditions and enables the same liposome batch to be functionalized with different peptides.

Surface conjugation uses chemical coupling reactions (maleimide-thiol, NHS ester-amine, click chemistry) to attach peptides directly to reactive groups on preformed PEGylated liposomes. This offers the most flexibility in peptide choice but can produce inconsistent conjugation density and may alter peptide conformation at the attachment site.

The choice of conjugation chemistry affects not just manufacturing but biological performance. Salahi and colleagues showed that tandem versus parallel conjugation of targeting ligands on the same liposome produced measurably different cellular uptake and cytotoxicity profiles, indicating that spatial arrangement of peptides matters as much as their identity.^[8]

Where the Field Is Heading

The convergence of peptide targeting with other nanotechnology advances is producing increasingly sophisticated systems. Stimulus-responsive peptides that activate only in the tumor microenvironment, dual-ligand systems that combine selectivity with penetration, and immune-priming peptide liposomes that train the immune system alongside delivering chemotherapy all represent active frontiers.

The integration of artificial intelligence into peptide design is accelerating discovery. Computational tools can now predict which peptide sequences will bind specific tumor receptors, estimate cell-penetrating ability, and model peptide-lipid interactions before synthesis. This shifts the bottleneck from peptide discovery to preclinical validation and manufacturing.

The broader principle, that short peptide sequences can convert a generic drug carrier into a tissue-specific delivery vehicle, extends well beyond oncology. The same engineering approach is being applied to cardiac tissue (cardiac homing peptides for myocardial infarction), brain delivery across the BBB (angiopep-2 for neurodegeneration), and inflammatory disease (CD47 mimicry for immune modulation). For related peptide approaches to cancer, see anticancer peptides: how they selectively kill tumor cells and endostatin: the anti-angiogenic peptide that starves tumors.

The Bottom Line

Peptide-targeted liposomes represent one of the most active areas in nanomedicine, with six major peptide classes (RGD integrins, BBB-crossing peptides, cell-penetrating peptides, tumor-homing peptides, immune-priming peptides, and stimulus-responsive peptides) driving preclinical development. Dual-ligand systems combining selectivity with penetration show the strongest results, particularly for brain tumors where both BBB crossing and tumor targeting are required. The central limitation remains clinical translation: no peptide-targeted liposome has reached Phase III despite extensive preclinical data, reflecting challenges in manufacturing consistency, EPR effect variability in humans, and the gap between mouse xenograft models and clinical oncology.

Frequently Asked Questions

What are peptide-targeted liposomes?

Peptide-targeted liposomes are spherical drug carriers made from phospholipid bilayers (similar to cell membranes) that have short peptide sequences attached to their surface. These peptides recognize and bind specific receptors overexpressed on tumor cells, converting passive drug carriers into active tumor-seeking vehicles. The liposome encapsulates chemotherapy drugs and delivers them directly to cancer cells through receptor-mediated endocytosis, potentially reducing side effects on healthy tissue.

How do RGD peptide liposomes target tumors?

RGD (arginine-glycine-aspartate) peptides bind integrin receptors alphavbeta3 and alphavbeta5, which are overexpressed on tumor blood vessel cells and many cancer cell types. When attached to liposome surfaces, RGD peptides guide the drug carrier to integrin-rich tumor tissue. The cyclic form (cRGDfK) binds with higher affinity than linear RGD. Studies show RGD-liposomes enhance cellular uptake and cytotoxicity against breast cancer cells compared to non-targeted liposomes (Mahmoudi et al., 2021).

Can liposomes cross the blood-brain barrier?

Peptide-functionalized liposomes can cross the blood-brain barrier using receptor-mediated transcytosis. Peptide-22 (targeting the LDL receptor) and angiopep-2 (targeting LRP1) are among the most studied BBB-crossing peptides for liposomal brain delivery. Dual-functionalized liposomes with both a BBB-crossing peptide and a tumor-targeting peptide (such as Peptide-22 plus cyclic RGD) achieved significantly higher brain tumor accumulation than single-peptide systems in glioma models (Chen et al., 2017).

Are peptide-targeted liposomes used in clinical practice?

No peptide-targeted liposome has reached Phase III clinical trials or clinical practice as of 2026. Non-targeted liposomes (such as Doxil) are clinically approved, and peptide-targeted versions show strong preclinical results, but the gap to clinical use remains due to manufacturing challenges, batch-to-batch variability in peptide conjugation, variable EPR effect in human tumors, and the complexity of scaling up multi-component nanosystems.

What is the difference between passive and active targeting in liposomes?

Passive targeting relies on the enhanced permeability and retention (EPR) effect, where leaky tumor blood vessels allow nanoparticles to accumulate in tumor tissue. Only about 0.7% of administered nanoparticles reach tumors this way. Active targeting adds ligands (such as peptides) to the liposome surface that recognize and bind specific receptors on cancer cells, triggering receptor-mediated endocytosis. Active targeting increases tumor cell uptake 5-8 fold over passive targeting in some models.

What is the PEG dilemma in liposome drug delivery?

The PEG dilemma refers to the conflict between stealth and targeting. PEGylation (coating liposomes with polyethylene glycol) extends circulation time by preventing immune recognition, but the PEG corona can physically block targeting peptides from reaching cell-surface receptors. Solutions include cleavable PEG linkers that detach in the tumor microenvironment (triggered by low pH or tumor-secreted enzymes like MMPs), exposing the targeting peptides only when the liposome reaches the tumor.